Abstract 1685: Investigating PAX8 interactions in ovarian cancer

Abstract Ovarian cancer is the most lethal gynecological cancer and there is a critical unmet need to develop novel therapies. The transcription factor, PAX8, is upregulated in ~80% of renal, ovarian, endometrial and thyroid tumors and its overexpression correlates with higher risk of death and recurrence. PAX8 represents a promising target because of its high specificity and low expected toxicity, but how it promotes tumorigenesis remains elusive. Using proximity labeling followed by mass spectrometry, we identified a list of PAX8 binding partners and have further confirmed these interactions at the genomic level through ChIP-seq and ATAC-seq. Our findings reveal novel PAX8 interactions and a potential therapeutic approach for ovarian cancer treatment. Citation Format: Kostianna Sereti, Anna Russo, Ryan Raisner, Karen Gascoigne. Investigating PAX8 interactions in ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1685.